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Abstract
Background: Although cross-sectional studies have linked higher body mass index (BMI) and type 2 diabetes (T2D) to
shortened telomeres, whether these metabolic conditions play a causal role in telomere biology is unknown. We therefore
examined whether genetic predisposition to higher BMI or T2D was associated with shortened leukocyte telomere length
(LTL).
Methodology: We conducted an analysis of 3,968 women of European ancestry aged 43–70 years from the Nurses’ Health
Study, who were selected as cases or controls in genome-wide association studies and studies of telomeres and disease.
Pre-diagnostic relative telomere length in peripheral blood leukocytes, collected in 1989–1990, was measured by
quantitative PCR. We combined information from multiple risk variants by calculating genetic risk scores based on 32
polymorphisms near 32 loci for BMI, and 36 polymorphisms near 35 loci for T2D.
Findings: After adjustment for age and case-control status, there was no association between the BMI genetic risk score and
LTL (b per standard deviation increase: 20.01; SE: 0.02; P=0.52). Similarly, the T2D genetic score was not associated with LTL
(b per standard deviation increase: 20.006; SE: 0.02; P=0.69).
Conclusions: In this population of middle-aged and older women of European ancestry, those genetically predisposed to
higher BMI or T2D did not possess shortened telomeres. Although we cannot exclude weak or modest effects, our findings
do not support a causal relation of strong magnitude between these metabolic conditions and telomere dynamics.
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Telomeres are repetitive DNA-protein complexes that protect
the ends of linear chromosomes and maintain genomic stability
[1]. They shorten with age, and biological factors such as oxidative
stress and inflammatory responses accelerate leukocyte telomere
length (LTL) attrition [2,3]. Thus, LTL may reflect cumulative
exposure to oxidative and inflammatory damage, serving as
a potential indicator of cellular aging [2]. Given that shortened
telomeres may be associated with increased incidence and
mortality of many age-related diseases [3,4,5,6,7,8,9], it is
important to better understand factors that influence telomere
biology.
Like telomere length, obesity and type 2 diabetes (T2D) have
been associated with oxidative stress, inflammation, and various
age-related outcomes [10,11,12,13]. However, whether these
metabolic conditions are associated with telomere length, as well
as the direction of these relations, are unclear. Studies have shown
associations between higher body mass index (BMI) [14,15,16,17]
or T2D [12,18,19,20] and telomere shortening, although some
have reported no relation [21,22,23]. While these associations may
be explained by heightened oxidative stress and inflammation
among obese or diabetic individuals, which promote telomere
erosion, recent findings have suggested telomeres may play a role
in the development of obesity or T2D [24,25]. The paucity of
prospective epidemiologic data, however, precludes the evaluation
of these conditions as a cause or consequence of shortened
telomeres. Moreover, as many studies reported unadjusted or age-
adjusted results, it is also unclear whether observed associations
were influenced by unmeasured confounders such as smoking or
physical activity.
To address these questions, we examined whether genetic
predisposition to higher BMI or T2D was associated with
shortened LTL among 3,968 women of European ancestry aged
43–70 years. Because each individual risk variant confers modest
risk, we combined genotype information across 32 established risk
variants near 32 loci for higher BMI [26], or 36 established risk
variants near 35 loci for T2D [27], to provide a global measure of
genetic predisposition. As genotypes are unaffected by telomere
shortening and independent of most confounders [28,29], we used
these genetic risk scores as proxies for higher BMI and T2D
exposure to evaluate whether these metabolic conditions play
a causal role in LTL dynamics.
Materials and Methods
Ethics statement
Completion of the self-administered questionnaire and sub-
mission of a blood sample were considered to imply informed
consent. The protocol for this study was approved by the Human
Research Committees at Brigham and Women’s Hospital, Boston,
MA, USA (IRB protocol number: 1999-P-010363).
Study population
The Nurses’ Health Study (NHS) prospective cohort was
established in 1976, when 121,700 female registered nurses aged
30 to 55 years completed and returned a mailed questionnaire.
Information on individual characteristics and new disease di-
agnoses has been updated biennially. From 1989 to 1990, 32,826
women provided blood samples and completed a questionnaire.
Details of the NHS and blood collection methods have been
described previously [30].
Among women who had previously provided a blood sample,
individuals of European ancestry were included as cases or
controls in genome-wide association studies of incident cancers,
cardiovascular disease, T2D, kidney stones, or open-angle
glaucoma [31,32,33,34]. Also among women who had previously
provided a blood sample, individuals were selected to participate
in nested case-control studies of LTL and incident cancers or
cardiovascular disease [35,36,37]. In studies of LTL, eligible cases
were identified starting any time after blood collection in 1989–
1990 (i.e., after telomere length assessment) up to June 1, 2008.
Participants included in the present analysis comprised those
selected in both genome-wide association studies and nested case-
control studies of telomeres and disease. The present analysis
excluded women with extreme LTL values (N=14) or LTL values
generated by non-standard assay conditions (N=218). The final
study population included 3,968 women of European ancestry.
Assessment of covariates
From the questionnaire completed at blood collection, we
assessed age, BMI (calculated as weight in kilograms/height in
meters
2), and date of blood collection. From questionnaires
administered before or at approximately the time of blood
collection, we assessed various anthropometric, reproductive,
and lifestyle factors, as well as the presence or history of chronic
diseases, including T2D status. We defined T2D as initially self-
reported diabetes subsequently confirmed by a validated supple-
mentary questionnaire [38,39,40]. T2D before 1998 was di-
agnosed using the National Diabetes Data Group criteria [40,41].
T2D after 1998 was diagnosed using the American Diabetes
Association criteria [42]. Using a semi-quantitative food frequency
questionnaire [43] administered in 1990, we assessed intakes of
dietary factors. Because the genetic score may best reflect long-
term BMI, we calculated a cumulative average measure by
averaging BMI data from all available questionnaires up to the
time of blood collection.
Measurement of relative leukocyte telomere length
Genomic DNA was extracted from peripheral blood leukocytes
using the QiAmp (Qiagen, Valencia, CA, USA) blood kit. We
assessed relative LTL using quantitative polymerase chain reaction
[44]. Average relative LTL was calculated as the exponentiated
ratio of Telomere repeat copy number to Single gene (36B4) copy
number (T/S) [45]. Laboratory technicians masked to participant
characteristics assayed each sample in triplicate. Quality control
samples were interspersed on each plate to assess variability. In all
nested case-control studies of LTL, coefficients of variation (CVs)
for the telomere and single gene assay were less than 4%, and CVs
for the exponentiated T/S ratio were less than 18%. Although this
assay provides a relative measurement of telomere length, T/S
ratios correlate well with absolute telomere lengths determined by
Southern blot (r=0.82, p,0.0001) [45].
Genotyping
Detailed information on genotyping and quality control
procedures has been described elsewhere [31,32,33,34]. Briefly,
DNA samples in various genome-wide studies were genotyped
using either Affymetrix 6.0 (Affymetrix, Santa Clara, CA, USA) or
Illumina arrays (HumanHap550k, 610Q, 660W, OmniExpress)
(Illumina, Inc., San Diego, CA, USA). After genotyping, quality
control filters were applied: We removed single nucleotide
polymorphisms (SNPs) with low minor allele frequencies, low call
rates, or genotype frequencies that significantly departed from
Hardy-Weinberg equilibrium, as well as individuals with outlying
missing genotype or heterozygosity rates, or those of non-
European ancestry as determined by principal components
analysis [46]. MACH [47] was used to impute autosomal SNPs
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as the reference panel.
Calculation of genetic risk scores
To reflect genetic predisposition to higher BMI, we selected 32
independent polymorphisms near 32 loci recently established in
a meta-analysis of genome-wide association studies that included
,250,000 individuals [26] (Table S1 in File S1). For genetic
predisposition to T2D, we selected 36 independent polymorphisms
near 35 loci that have been robustly replicated in genome-wide
association studies of T2D [27] (Table S2 in File S1). Most BMI or
T2D risk variants were genotyped or had high imputation quality
(MACH ‘Rsq’$0.8). In sensitivity analyses, results were essentially
unchanged after excluding SNPs imputed with MACH Rsq,0.8
(3 BMI SNPs; 6 T2D SNPs).
To maximize the strength of the genetic scores as proxies for
BMI and T2D, we calculated the scores using a weighted method
that accounted for the strength of prior associations. We multiplied
the number of risk alleles (i.e., allele associated with higher BMI or
risk of T2D) for each SNP by its previously published relative
effect size (b-coefficient) before summing the products. For
interpretability, the weighting process created a score for which
each unit corresponded to an average risk allele. Detailed
calculations for the weighted genetic scores have been described
previously [26,38]. Risk variants in the scores were chosen
specifically based on their established effects on BMI or T2D,
and we assumed these scores were not associated with telomere
length through factors or mechanisms unrelated to these
conditions [28,29]. Few participants had incomplete genotype
data (N missing 1 or 2 SNPs: BMI, 82; T2D, 45). We assigned
missing genotypes the average genotype at that locus. In sensitivity
analyses, exclusion of individuals with missing genotypes did not
alter the findings.
Statistical analyses
We calculated the natural logarithm of LTL to better
approximate normality. Among participants in each nested case-
control set, we identified outlying LTL values using the
generalized extreme studentized deviate many-outlier procedure
[48]. To ensure comparability across sets for relative LTL values,
we computed z-scores of LTL for individuals in each set using the
formula z-score =( x2m)/s, where x is an individual’s LTL, m is the
set-specific mean LTL, and s is the set-specific standard deviation
of LTL.
To analyze additive associations (0, 1, or 2 copies of the risk
allele) between each BMI- or T2D-related variant and LTL, we
used linear regression adjusted for age and case status. We
conducted exact binomial tests to assess whether more risk variants
than expected by chance were significantly associated with shorter
telomeres. In addition, we performed False Discovery Rate (FDR)
corrections to account for multiple statistical tests [49]. To
evaluate the suitability of the genetic score as a proxy for BMI,
we estimated least squares mean BMI using generalized linear
models. For T2D, we estimated odds ratios and 95% CIs using
unconditional logistic regression.
To examine associations between the genetic scores and LTL,
we estimated adjusted least squares mean LTL (z-scores) by
genetic score quartiles using generalized linear models adjusted for
age and case status. We also considered the following factors
potentially associated with LTL: date of blood collection, nested
case-control study of LTL, genome-wide association study, pack-
years of smoking, menopausal status, past or current post-
menopausal hormone therapy, physical activity, paternal age,
and family history of diabetes. As results were similar after
including these variables, they were omitted from the primary
models. We tested for linear trend by separately including each
genetic score as a continuous predictor in multivariable models.
Because the genetic effects of BMI- or T2D-related variants
may vary by lifestyle [50,51], we conducted exploratory analyses
to evaluate whether associations differed by unhealthy lifestyle
pattern expected to contribute to weight gain, calculated by
creating low- or high-risk variables using the median value of four
lifestyle factors: physical activity, sitting, sweetened beverage
intake, alternate healthy eating index [52], and then summing
the number of high-risk variables. We used partial F-tests to
compare nested models with and without interaction terms
between the genetic scores and lifestyle variable.
P-values were 2-sided and P#0.05 was considered significant.
All statistical analyses used SAS, Version 9.2, software (SAS
Institute Inc, Cary, NC) or R, Version 2.11.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
The mean age of participants was 59.2 years. As expected,
women with longer telomeres were younger, less likely to be obese,
and less likely to have T2D compared with women with shorter
telomeres (Table 1). After adjustment for potential predictors of
telomere length (e.g., age, case status, smoking, physical activity,
menopausal status, postmenopausal hormone therapy), LTL was
inversely associated with age (20.065 SD per 5-yr increase; SE:
0.014; P,0.001), BMI (20.043 SD per 5 kg/m
2 increase; SE:
0.020; P=0.031), and T2D (20.116 SD for diabetics vs non-
diabetics; SE: 0.060; P=0.055). In addition, women with longer
telomeres smoked fewer pack-years, tended to be more active, and
Table 1. Age and age-adjusted characteristics of 3,968
women in the Nurses’ Health Study by telomere length (z-
score), 1989–1990.
a,b
Quintile of LTL (z-score)
Characteristic 5
th (longest) 3
rd 1
st (shortest)
N 790 791 795
LTL (z-score) 1.3 (0.4) 20.01 (0.1) 21.4 (0.5)
Age at blood collection (yrs)
c 58.8 (6.7) 58.9 (6.3) 60.0 (6.4)
Body mass index (kg/m
2)
18.5–,25 51.1% 49.5% 50.5%
25–,30 31.3% 31.6% 30.0%
$30 16.5% 18.0% 18.2%
Type 2 diabetes 6.9% 7.3% 8.8%
Pack-years of smoking 13.6 (20.1) 14.9 (20.6) 14.9 (20.7)
Total activity in 1988
(MET-hrs/wk)
16.1 (17.9) 15.6 (16.7) 15.3 (17.7)
Ever oral contraceptive use 43.1% 40.5% 44.0%
Postmenopausal 83.3% 81.9% 82.7%
Current HT use 41.3% 42.5% 43.9%
Family history of diabetes 28.2% 30.9% 28.0%
Abbreviations: LTL, leukocyte telomere length; MET-hrs/wk, metabolic
equivalent hours of activity per week; HT, postmenopausal hormone therapy.
aValues are means(SD) or percentages, and standardized to the age distribution
of the study population at blood collection.
bValues may not add to 100% because of missing data.
cValue not age-adjusted.
doi:10.1371/journal.pone.0052240.t001
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(Table 1).
After adjustment for age and case status, BMI-related variants
near GNPDA2 (rs10938397) and RPL27A (rs4929949), as well as
one variant for T2D near RBMS1-ITGB6 (rs7593730) were
nominally associated (P#0.05) with shorter LTL (Tables S1 and
S2 in File S1). However, the number of associated variants did not
exceed that expected by chance (P=0.19 for BMI; P=0.60 for
T2D), and these variants became non-significant after False
Discovery Rate correction for multiple testing.
For body mass, the mean genetic risk score was 29.2 and the
standard deviation (SD) was 3.9; for T2D, the mean score was 38.4
and the SD was 4.0. As expected, positive associations among the
genetic risk scores, body mass, and T2D were highly significant,
suggesting these scores were reasonable proxies for BMI or T2D
(Table 2). After adjustment for age and case status, each SD
increase in the BMI genetic score was associated with a 0.62 kg/
m
2 increase in BMI (SE: 0.06; P,0.001), and each SD increase in
the T2D score was associated with a 27% increased odds of T2D
(95% CI: 1.13, 1.43; P,0.001). Moreover, the test statistics were
.10 (the convention for identifying sufficiently strong genetic
proxies for environmental exposures [53]) for associations between
the scores and BMI (F=29.0) or T2D (x
2=12.7).
After combining the number of risk alleles across multiple risk
variants, the scores for body mass and T2D were not associated
with LTL (Table 3). For the BMI score, the least squares mean
LTL (z-score) across quartiles of the genetic risk score were
20.005, 20.02, 20.02, and 20.04, respectively (P-trend=0.52).
For the T2D score, the least squares mean LTL (z-score) across
quartiles of the genetic risk score were 0.02, 20.05, 20.07, and
0.01, respectively (P-trend=0.69). Additional adjustment for BMI
or T2D did not appreciably alter the findings. To assess whether
the inclusion of cases influenced our findings, we repeated our
analyses after restricting to women selected as controls (N=2,222),
as well as after excluding women selected as T2D cases (N=310
excluded); we observed similar results to those from the main
analyses (data not shown).
For the T2D genetic risk score, results were consistent across
unhealthy lifestyle pattern (P-interaction=0.34). For the BMI
score, however, estimates appeared stronger among women with
an unhealthy lifestyle pattern compared to those with a healthy
lifestyle (Figure S1 in File S1), although this difference was not
statistically significant (P-interaction=0.11).
Based on the correlations in our population between the genetic
scores and BMI or T2D, as well as the correlations in the existing
literature between these conditions and LTL, we calculated the
statistical power in our study to detect an association between the
scores and LTL (a=0.05). Given that 2% of the variability in BMI
was explained by variability in the genetic score, our data provided
80% power to detect an association between the score and LTL if
at least 9% of the variability in LTL is explained by variability in
BMI. Estimates of 1–18% have been reported among studies that
identified an association [15,16,17,54,55,56]. For T2D, 0.4% of
the variability was explained by variability in the genetic score.
Our data provided 80% power to detect an association between
the score and LTL if at least 50% of the variability in LTL is
explained by T2D status. Previous findings have been inconsistent,
with reported estimates of ,1–59% [18,19,20,57,58,59]. These
calculations suggest our data were underpowered to detect weak or
modest effects; however, they provided sufficient power to detect
previously reported associations of greater magnitude.
Discussion
In this population of middle-aged and older women of
European ancestry, we examined the joint effects of established
BMI- or T2D-related risk variants on LTL. After combining data
from multiple risk variants, women genetically predisposed to
higher BMI or T2D did not possess shortened telomeres after
adjustment for age and case status.
While our study is the first to examine the association between
genetic predisposition to higher BMI or T2D and telomere length,
many cross-sectional studies have directly examined the relation
with these metabolic conditions. For BMI, some studies
[14,15,16,17,55,56,60,61,62], including the present analysis,
observed an inverse association with telomere length, while others
reported no association [8,21,22,63]. Similarly for T2D, most
studies [12,18,19,20,57,58,59,64,65], including the present anal-
ysis, observed an inverse association despite a large variation in the
strength of the relation. Although the reasons for these
Table 2. Associations among body mass index, type 2 diabetes, and their respective genetic risk scores, Nurses’ Health Study,
1989–1990.
Quartiles of genetic risk score
1
st 2
nd 3
rd 4
th P trend
b
Body mass index
N – 973 1036 960 999 –
Score range (median) – 16.0–26.4 (24.6) 26.5–29.2 (27.9) 29.3–31.8 (30.5) 31.9–42.9 (33.6) –
LS mean kg/m
2 (95% CI)
a – 23.6 (23.4, 23.9) 24.3 (24.0, 24.5) 24.7 (24.4, 25.0) 25.3 (25.0, 25.5) ,0.001
b (SE) per SD of score 0.62 (0.06) – – – – –
Type 2 diabetes
N (cases) – 989 (60) 999 (64) 974 (78) 1006 (100) –
Score range (median) – 24.1–35.6 (33.7) 35.7–38.4 (37.0) 38.5–41.1 (39.6) 41.2–52.9 (43.0) –
Odds ratio (95% CI)
a – 1.00 (ref) 1.02 (0.71, 1.48) 1.38 (0.97, 1.96) 1.70 (1.22, 2.38) ,0.001
OR (95% CI) per SD of score 1.27 (1.13, 1.43) – – – – –
Abbreviations: LS mean, least squares mean; CI, confidence interval; SD, standard deviation; SE, standard error.
aAdjusted for age in years (continuous), case status (case, control).
bP values are 2-sided.
doi:10.1371/journal.pone.0052240.t002
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population characteristics. In addition, these analyses had two
important limitations. First, unmeasured confounders may have
influenced findings. For example, several studies reported only
unadjusted [22,23,58,62] or age-adjusted results [12,15,57,63],
increasing the possibility of unmeasured confounding by factors
such as age, smoking, or physical activity (i.e., potential predictors
of higher BMI or T2D and telomere length). Second, cross-
sectional analyses were unable to test the direction of the
association between higher BMI or T2D and telomere shortening,
although several studies hypothesized that telomere shortening
may be a consequence of higher body mass or T2D due to
elevated oxidative stress and inflammation [10,11,12,13]. In the
present analysis, we used the genetic risk scores as proxies for BMI
and T2D exposure to test the causal role of these metabolic
conditions in telomere biology [28]. As genetic variants are
generally unaffected by environmental factors, our observations
were minimally influenced by confounding. More importantly,
telomere length is unlikely to affect genotypes, which enabled us to
test whether higher BMI or T2D precede telomere shortening.
Because neither genetic score was associated with LTL in the
present analysis, we did not find evidence of a causal relation of
strong magnitude, as findings from some studies suggested
[17,20,55,61], between higher BMI or T2D and LTL among
middle-aged or older women of European ancestry.
Few prospective studies have examined whether higher BMI or
T2D predict telomere shortening. Our findings were consistent
with those of Farzaneh-Far et al. [66], who observed no association
among 608 individuals between baseline BMI or T2D and
subsequent telomere shortening over five years. O’Callaghan et al.
[54], however, observed that men who lowered their BMI had
increased telomere length over one year, although this study
included only 54 men and requires replication in a larger study of
women. Findings from recent studies have suggested that telomere
length may also play a role in the pathogenesis of these metabolic
conditions, which may account in part for previous cross-sectional
associations. Njajou et al. [24] observed among 2,721 individuals
that, unexpectedly, longer telomeres were associated with greater
increases in BMI over seven years. In addition, Zee et al. [25]
observed that genetic variants in telomere-related genes may
predict risk of T2D among ,22,000 women of European ancestry.
Although requiring replication, these findings and those from the
present analysis suggest relations among BMI, T2D, and telomere
length are complex. Thus, although higher BMI or T2D may play
a causal role of weak or modest magnitude in telomere shortening,
these may not completely explain the observed cross-sectional
associations.
Our null findings should be interpreted with caution given
several limitations of our study. First, although the genetic risk
scores captured the combined information from established
genetic factors for higher BMI and T2D [26,38,67,68], they
accounted for only a small amount of the variability in these
conditions – indicating that the influence of these scores on higher
BMI or T2D is likely weak relative to the influence of other factors
(e.g., environmental predictors, gene-environment interactions).
Thus, when examining the null association with LTL it is
important to consider that these scores do not capture compre-
hensively exposure to higher BMI or T2D. More specifically, they
reflect a component of the genetic risk to these conditions and do
not capture the non-genetic components, which may be relevant
for LTL. Although this is an important limitation of our approach,
large prospective studies of telomere length are often impractical
as they require repeated measurements of LTL over time. Thus,
using genetic scores as proxies for exposures to evaluate causal
relations, with careful consideration of the limitations, provides
a feasible alternative. In addition, future studies can use a similar
approach by using telomere-related genetic variants as proxies to
evaluate whether shortened telomeres predict higher BMI or risk
of T2D, similar to Zee et al. [25].
Second, because the genetic scores were weak proxies of higher
BMI and T2D, our data were underpowered to detect causal
relations of weak or modest magnitude among BMI, T2D, and
LTL. While our data provided sufficient power to detect large
effects, the detection of weak associations using these scores
requires large study populations that may only be available in
meta-analyses (e.g., N.33,000 unrelated individuals if BMI or
T2D explains 1% of the variability in LTL). Alternatively, future
studies can potentially leverage the presence of gene-environment
interactions to improve statistical power. For example, studies may
be able to detect weak or modest effects on LTL by focusing on
Table 3. Least squares mean telomere length (z-score) and 95% CI by genetic risk scores of common risk variants associated with
higher body mass index or type 2 diabetes, Nurses’ Health Study, 1989–1990.
Quartiles of genetic risk score
1
st 2
nd 3
rd 4
th P trend
b
Body mass index
N – 973 1036 960 999 –
Score range (median) – 16.0–26.4 (24.6) 26.5–29.2 (27.9) 29.3–31.8 (30.5) 31.9–42.9 (33.6) –
LS mean LTL (95% CI)
a – 20.005(20.07, 0.06) 20.02 (20.08, 0.04) 20.02 (20.08, 0.04) 20.04 (20.11, 0.02) 0.52
b (SE) per SD of score 20.01 (0.02) – – – – –
Type 2 diabetes
N – 989 999 974 1006 –
Score range (median) – 24.1–35.6 (33.7) 35.7–38.4 (37.0) 38.5–41.1 (39.6) 41.2–52.9 (43.0) –
LS mean LTL (95% CI)
a –0 . 0 2 ( 20.04, 0.08) 20.05 (20.11, 0.01) 20.07 (20.13, 20.004) 0.01 (20.05, 0.07) 0.69
b (SE) per SD of score 20 . 0 0 6 ( 0 . 0 2 ) – –– ––
Abbreviations: LS mean LTL, least squares mean leukocyte telomere length (z-score); CI, confidence interval; SD, standard deviation; SE, standard error.
aAdjusted for age in years (continuous), case status (case, control).
bP values are 2-sided.
doi:10.1371/journal.pone.0052240.t003
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better predict BMI or T2D [50,51,69]. While our data were
underpowered to detect interactions, we observed that estimates
between the BMI score and LTL appeared more pronounced
among women with unhealthy lifestyle patterns expected to
increase weight gain, supporting this possibility.
Third, because blood samples were stored on average for
19 years before LTL measurement, LTL degradation during
storage is a possible concern. Because technicians were masked to
participants’ genotypes when measuring LTL, degradation would
likely attenuate the results. However, years of sample storage was
not correlated with telomere length in our population (rs=20.01,
p=0.64), and previous studies in the NHS have identified
significant associations with telomere length [70,71,72], further
supporting the validity of our telomere length measurement.
Lastly, our study population comprised women of European
ancestry, which minimized population stratification. However,
because telomere dynamics may differ among African Americans
and Hispanics [7,73,74], our null findings may not be generaliz-
able to women of other ethnicities.
In summary, we found that genetic predisposition to higher
BMI or T2D, estimated by genetic risk scores, was not associated
with shortened telomeres among middle-aged and older women of
European ancestry. Although we cannot exclude weak or modest
effects, our findings do not support a causal role of strong
magnitude for these metabolic conditions in telomere dynamics.
Future efforts to detect causal relations of weaker magnitude will
likely require meta-analyses of existing and future genetic studies
of telomere length, or large prospective studies with repeated
telomere length measurements.
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